Book a visit

Home  /  About  /  Curriculum Vitae

About Dr. Sangal

R. Bart Sangal, MD — Curriculum Vitae

R. Bart Sangal MD is board-certified in Sleep Medicine and Obesity Medicine · Clinical Professor, Oakland University William Beaumont School of Medicine · Director, Sleep and Obesity Medicine.

For Dr. Sangal’s ~50 peer-reviewed publications with abstract links, see the Publications page.

Book a visit
Publications

Education

  • Delhi University, Delhi, India, Pre-Medical, 1972.
  • All India Institute of Medical Sciences, New Delhi, India, M.B.,B.S., 1978

Postgraduate Training

  • SUNY-Upstate Medical Center, Syracuse, NY, Internship in Medicine-Psychiatry, Jan 1979 -Dec 1979
  • Johns Hopkins University Hospitals, Baltimore, MD, Residency in Psychiatry, Jan 1980 – Dec 1982
  • NIH/Johns Hopkins, Baltimore, MD, Fellowship in Psychophysiology, July 1982 – June 1983

Faculty Appointments

  • Oakland University-William Beaumont School of Medicine, Departments of Psychiatry and Family Medicine
    • Professor, 2010-current.
  • Wayne State University School of Medicine, Dept. of Psychiatry & Behavioral Neurosciences
    • Associate Professor 2006-2010.
    • Assistant Professor 1993-2000
    • Instructor 1984-1993

Professional Appointments

  • Director of Sleep & Attention Disorders Institutes (Clinical Neurophysiology Services, P.C.), Sterling Heights, MI, Sep. 1986 – Dec. 2025.
  • Director of Sangal Research Foundation, Bloomfield Hills, MI.

Major Professional Societies & Leadership Positions

National Medical Boards and Committees

  • American Academy of Sleep Medicine
    • Chair, National Healthy Sleep Awareness Project Public Information Workgroup, 2013 – 2018
    • Chair, The Business of Sleep Medicine Course, 2008 – 2010
    • Member, AASM Presidential Committee on Coding and Compliance, 2009 – 2010
    • Member, Committee to Revise the International Classification of Sleep Disorders, 2002-2004
    • Member, Board of Directors, 1996-1999
    • Chair, Health Policy Committee, 1994-1996
    • Co-Chair, Reimbursement Committee, 1991-1994
    • Member, Government Affairs Committee, 1992-1994
  • American Medical Association
  • Electroencephalography and Clinical Neuroscience Society

State and local medical boards and committees

  • Michigan Academy of Sleep Medicine
    • Past-President, 2015
    • President, 1989, 2013-2014
    • President-Elect, 2011-2012
    • Director, 2009 – 2010
    • Chair, Standards of Practice Committee, 1990-2019
  • Michigan State Medical Society
    • Member, Third Party Payer Liaison Committee, 1994-2006
    • Member, Blue Cross-Blue Shield Liaison Committee, 1989-1994
    • Alternate Delegate to MSMS Young Physicians Section from OCMS, 1988-90
  • Member, Oakland County Medical Society
    • Member, Board of Directors, 2011-2014
    • Delegate; 2008-2011
    • Member, Legislation Committee, 1988-2002; 2007-2014
    • Member, Bulletin Committee, 1988-1998; 2007-2011
    • Member, Public Information Committee, 1988-89
  • Member, United Physicians, until 2026
    • Member, Board of Directors, 2016-2019
    • Member, ACO Board of Directors, 2019-2021

Other boards and committees

  • Orange Lake Homeowners Association. Bloomfield Twp, MI
    • President for several years
  • Island, Lower Long, and Forest Lake Property Owners Association, Bloomfield Twp, MI

Medical Licensure

Licensed in Michigan, Massachusetts, and California.

Board Certification — R. Bart Sangal MD

  • Diplomate, Sleep Medicine, American Board of Psychiatry and Neurology, 2007, re-certified 2016 (expiry Dec. 31, 2026), certificate no. 273
  • Diplomate, Clinical Neurophysiology, American Board of Psychiatry and Neurology, 1992, re-certified 2021 (expiry Dec. 31, 2031), certificate no. 170
  • Diplomate, Psychiatry, American Board of Psychiatry and Neurology, 1985, score 97% ile (never expires), certificate no. 27139
  • Certified Principal Investigator, Academy of Physicians in Clinical Research, 2002, re-certified 2024 (expiry Nov. 30, 2026)
  • Diplomate, American Board of Sleep Medicine, 1985, with highest score in the nation in the Part I examinations.
  • Diplomate, American Board of Obesity Medicine, 2025.

Honors / Awards

  • Awarded the Mark Hatfield Award for Public Policy by the American Academy of Sleep Medicine in 2006.
  • Awarded the President’s Award for Excellence in Clinical Sleep Medicine by the Michigan Academy of Sleep Medicine in 2015.

Service

  • Oakland University William Beaumont School of Medicine, Departments of Psychiatry & Family Medicine, Professor, 2010 – now. Screener for Medical Schools admissions, 2011 – 2024.
  • Patient Care: Director of Sleep and Obesity Medicine, Bloomfield Hills, MI, Jan 2026 – now. Director of Sleep/Attention Disorders Institutes, Troy/Sterling Hts, MI, Sep 1986 – Dec 2025. Before that, independent contractor with a group practice which no longer exists (PCM Clinic, Mt. Clemens, MI), July 1983 – Aug. 1986.
  • Professional Consultation: Director of Sangal Research Foundation, a non-profit foundation for education and research in Clinical Neurophysiology.
  • Community: Numerous radio, TV and newspaper interviews with Detroit News, Detroit Free Press, Oakland News, The Observer/Eccentric, WWJ, TV Channels 2, 4, 7, 50.

Service for Peer-Reviewed Journals

  • Editorial Board Membership: Member, Editorial Board, Clinical Electroencephalography & Neuroscience, 1997-now.
  • Review of Manuscripts: Reviewed manuscripts submitted for Sleep, Sleep Medicine, Clinical EEG & Neuroscience, Clinical Neurophysiology, JAMA, Annals of Internal Medicine, Psychiatry Research, European Journal of Paediatric Neurology, Internation Journal of Psychophysiology, Journal of Psychosomatic Research, Neuroscience Letters, and several other journals.

Other Scholarly Service

  • Chair, American Academy of Sleep Medicine Business of Sleep Medicine Course, 2008-2010.

Teaching

  • Oakland University William Beaumont School of Medicine, Departments of Pscyhiatry and Family Medicine, Professor, 2010-now.
    • Lectures on Sleep Medicine offered to residents
  • Wayne State University School of Medicine, Dept. of Psychiatry & Behavioral Neurosciences, Instructor 1984-1993, Assistant Professor 1993-2000, Associate Professor 2006-2010.
    • Subspecialty day rotations in Sleep Medicine/ Clinical Neurophysiology offered to medical students
    • Month-long rotations in Sleep Medicine offered to medical students and residents
    • Lectures on Sleep Medicine and Clinical Neurophysiology to medical students and residents
    • Mentorship for medical students and residents doing research in Sleep Medicine and Clinical Neurophysiology.

CLINICAL TRIALS/ACTIVITIES

● A Nine Week Placebo-Controlled, Double-Blind, Randomized, Parallel-group study of the efficacy of two fixed doses (200 mg, 400 mg) of oral Modafinil in patients with Narcolepsy; followed by An 40 week, open-label, flexible-dose continuation study, followed by recurrent 48 week open-label extensions; 1994-1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
● Cognex: Neuropsychiatric Testing and Assessment of Caregiver Time Study; 1996. Principal Investigator: R. Bart Sangal, M.D. Supported by Parke-Davis Medical Research.
● A Double-Blind Flexible Dose Study of Transdermal Buspirone in the Treatment of Children with Attention-Deficit Hyperactivity Disorder; 1997-1998. Principal Investigator: R. Bart Sangal, M.D. Supported by Bristol-Myers Squibb Co.
● A Double-Blind Fixed Dose Study of Transdermal Buspirone in the Treatment of Children with Attention-Deficit Hyperactivity Disorder; followed by An Open-Label, Long Term, Flexible Dose Safety Study of Transdermal Buspirone in the Treatment of Childhood Attention-Deficit Hyperactivity Disorder; 1998. Principal Investigator: R. Bart Sangal, M.D. Supported by Bristol-Myers Squibb Co.
● An Open-Label, Long Term, Flexible Dose Safety Study of Transdermal Buspirone in the Treatment of Childhood Attention-Deficit Hyperactivity Disorder; 1997-1998. Principal Investigator: R. Bart Sangal, M.D. Supported by Bristol-Myers Squibb Co.
● The Pharmacokinetics of Buspirone during Transdermal Administration to Children with Attention-Deficit Hyperactivity Disorder, with and without RitalinR Therapy; 1998. Principal Investigator: R. Bart Sangal, M.D. Supported by Bristol-Myers Squibb Co.
● A Six-Week Open-Label Study of Safety and Efficacy of ProvigilR (Modafinil) in patients switching from stimulant therapy for Narcolepsy-associated Excessive Daytime Sleepiness; 1998-1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
● A Double-Blind, Randomized, Parallel-Design, Placebo-Controlled Trial of d-threo-Methylphenidate Hydrochloride (d-MPH) and dl-threo-Methylphenidate Hydrochloride (dl-MPH) in Children with Attention Deficit Hyperactivity Disorder (ADHD); 1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Celgene Corporation.
● A Double-Blind, Randomized, Parallel-Design, Placebo-Controlled Withdrawal Trial of d-threo-Methylphenidate Hydrochloride (d-MPH) in Children with Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responding to d-MPH; 1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Celgene Corporation.
● A Six Month Open-Label Safety Trial of d-threo-Methylphenidate Hydrochloride (d-MPH) in Children with Symptoms of Attention Deficit Hyperactivity Disorder (ADHD); 1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Celgene Corporation.
● A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study evaluating the efficacy and safety of Buspirone Hydrochloride (15-60 mg/day) in Children and Adolescents (aged 6 to 17) with Generalized Anxiety Disorder; 1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Bristol-Myers Squibb Co.
● A Double-Blind, Placebo-Controlled, Multi-Center, Randomized, Parallel-Group study of the effect of four weeks of Provigil (Modafinil) treatment on Excessive Daytime Sleepiness in Obstructive Sleep Apnea Patients treated with Nasal Continuous Positive Airway Pressure; 1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
● A Double-Blind, Placebo-Controlled Study of Modified Release (MR) Methylphenidate in Children with ADHD; 1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Medeva Development.
● A Phase III Open-Label Safety and Efficacy Study of Tomoxetine Hydrochloride in Outpatients with ADHD, Ages 6 to 18 years; 2000-2002. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● A Phase III Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges (mg/kg/day) of Tomoxetine with Placebo in Child and Adolescent Outpatients with ADHD, Aged 8 to 18 years; 2000-2002. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● A Multicenter, double-blind, randomized, placebo-controlled, parallel-group, evaluation of the safety and efficacy of a modified-release oral dosage form of Methylphenidate-HCl (Ritalin-QD) in children with ADHD; 2000. Principal Investigator: R. Bart Sangal, M.D. Supported by Novartis Pharmaceuticals Corporation.
● A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group study to evaluate the Safety and Efficacy of 12 weeks of 2 Oral Doses (200 mg and 400 mg once daily) of Provigil (Modafinil) as Treatment for Adults with Excessive Daytime Sleepiness associated with Obstructive Sleep Apnea/Hypopnea Syndrome followed by a 9-month open-label extension; 2000-2001. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
● An Efficacy, Safety and Tolerability Study of (S)-Zopiclone in subjects with Transient Insomnia (First Night Effect Model); 2000-2001. Principal Investigator: R. Bart Sangal, M.D. Supported by Sepracor, Inc.
● A Phase III Randomized, Double-Blind Comparison of Placebo and Tomoxetine in Adult Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder; 2000-2001. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● A Long-Term, Open Label, safety study of Tomoxetine Hydrochloride in Patients, 6 Years and Older; 2000-2007. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● A Randomized, Double-Blind, Placebo-Controlled, Single Dose First Night Effect Sleep Laboratory Study of Two Doses of TAK-375 in Health Adult Volunteers; 2000. Principal Investigator: R. Bart Sangal, M.D. Supported by Takeda America Research and Development Center, Inc.
● A Phase 3 Open-Label Safety and Efficacy Study of Tomoxetine Hydrochloride in Pediatric Outpatients (6 to 18 years) with ADHD; 2001. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● A Long-Term, Open Label, safety study of Tomoxetine Hydrochloride in Adult Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder; 2001-2007. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● Efficacy, Tolerability, and Safety of Once-Daily Tomoxetine Hydrochloride versus Placebo in Children with Attention-Deficit/Hyperactivity Disorder; 2001. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● Sleep and Cognitive/Neuropsychological Function in Children with Attention-Deficit/Hyperactivity Disorder Before and During Treatment with Tomoxetine Hydrochloride and Stimulants; 2001-2002. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to assess the efficacy and safety of NBI-34060 in Elderly Patients with Chronic Insomnia, 2001. Principal Investigator: R. Bart Sangal, M.D. Supported by Neurocrine Biosciences, Inc.
● A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride, Extended-Release Methylphenidate Hydrochloride (Concerta), and Placebo in Pediatric Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder, 2002-2003. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● Comparison of efficacy and safety of Zolpidem_MR 12.5 mg and placebo in patients with primary insomnia. A double-blind, randomized, placebo-controlled, parallel-group study, 2002. Principal Investigator: R. Bart Sangal, M.D. Supported by Sanofi-Synthelabo.
● A Double-Blind Study of Treatment Optimization with Atomoxetine Hydrochloride in Adults with DSM-IV Attention-Deficit/Hyperactivity Disorder, 2002-2003. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● A Randomized, Double-Blind, Active- and Placebo-Controlled 4-Way Crossover Study of the Safety and Efficacy of PD 0200390, Zolpidem, and Placebo in Primary Insomnia, 2002. Principal Investigator: R. Bart Sangal, M.D. Supported by Pfizer, Inc.
● A Phase III, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Safety and Efficacy of TAK-375 in Elderly Subjects with Chronic Insomnia, 2002-2003. Principal Investigator: R. Bart Sangal, M.D. Supported by Takeda Pharmaceuticals.
● A Phase III, Randomized, Double-Blind, Placebo-Controlled, PSG Plus Outpatient Study to Determine the Safety and Efficacy of TAK-375 in Adults with Chronic Insomnia, 2003. Principal Investigator: R. Bart Sangal, M.D. Supported by Takeda Pharmaceuticals.

● A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects with Chronic Insomnia, 2003-2004. Principal Investigator: R. Bart Sangal, M.D.,Supported by Takeda Pharmaceuticals.
● A 5-week, multicenter, double-blind, randomized, placebo-controlled, fixed-dose study of the efficacy and safety of FocalinTM LA (dexmethylphenidate hydrochloride extended-release capsules) administered once daily in adults with Attention-Deficit/Hyperactivity Disorder, 2003. Principal Investigator: R. Bart Sangal, M.D. Supported by Novartis Pharmaceuticals.
● A 6-month, open-label extension to a 5-week, multicenter, double-blind, randomized, placebo-controlled, fixed-dose study of the efficacy and safety of FocalinTM LA (dexmethylphenidate hydrochloride extended-release capsules) administered once daily in adults with Attention-Deficit/Hyperactivity Disorder, 2003. Principal Investigator: R. Bart Sangal, M.D. Supported by Novartis Pharmaceuticals.
● A 9-week, randomized, double-blind, placebo-controlled, flexible-dosage (up to 425 mg/day), parallel-group study to evaluate the efficacy and safety of Modafinil (Film-coated Tablet) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, 2004. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
● A 1-year, open-label, flexible-dosage study to evaluate the safety and continued efficacy of modafinil (Film-coated Tablet) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, 2004-2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
● A double-blind study of functional outcomes with Atomoxetine-Hydrochloride and Placebo in adult outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder, 2004-2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of Gabitril (4, 6, 8, and 10 mg) treatment in adult patients with primary insomnia, 2004. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
● A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of Gabitril (2, 4, 6, and 8 mg) treatment in elderly patients with primary insomnia, 2004. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
● A 12-month, open-label study to evaluate the safety and efficacy of Gabitril at dosages up to 10 mg/day in adults with primary insomnia, 2004. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
● A 12-month, open-label study to evaluate the safety and efficacy of Gabitril at dosages up to 8 mg/day in elderly adults with primary insomnia, 2004-2005. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
● A North American, 4-week, multicenter, phase IIB double-blind, placebo-controlled, randomized, multiple dose, parallel-group study of the efficacy and safety of 0.5 mg, 1.0 mg and 2.0 mg M100907 tablets in the treatment of sleep maintenance insomnia, 2004-2005. Principal Investigator: R. Bart Sangal, M.D. Supported by Aventis, Inc.
● Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults with ADHD Over an Extended Period of Time (6 Months): With a Brief Evaluation of Executive Cognition, 2004-2005. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● An Exploratory Open-Label Safety and Efficacy Study of Atomoxetine in the Treatment of Mild Obstructive Sleep Apnea, 2004-2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● A randomized, 4-way cross-over, double-blind, placebo-controlled, multicenter dose-finding trial with three dosages of Org 50081 in patients with Primary Insomnia, 2004-2005. Principal Investigator: R. Bart Sangal, M.D. Supported by Organon.
● A double-blind, randomized, placebo-controlled, multicenter, 30-night polysomnographic study of MK-0928 in Elderly patients with Primary Insomnia, 2005-2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Merck & Co., Inc.
● A double-blind, randomized, placebo-controlled, multicenter, 30-night polysomnographic study of MK-0928 in Adult patients with Primary Insomnia, 2005-2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Merck & Co., Inc.
● A Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to assess the long term efficacy and safety of doxepin HCl in Primary Elderly Insomnia patients with sleep maintenance difficulties, 2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Somaxon Pharmaceuticals, Inc.
● Efficacy, safety and tolerability of zolpidem in the treatment of children aged 6 to 17 years with ADHD-associated insomnia. A multicentre, randomized, double-blind, placebo-controlled study, 2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Sanofi-Aventis.
● A 6-week, double-blind, placebo-controlled, parallel-group randomized-withdrawal study to evaluate the continued efficacy of modafinil treatment at dosages up to 425 mg/day in patients with Attention-Deficit/Hyperactivity Disorder who are responders to modafinil treatment, followed by a 12-month open-label extension period, 2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
● A 28 day, polysomnographic and subjective assessment of GW679769, 10 and 30 mg, for the treatment of Primary Insomnia: A randomized, double-blind, parallel-group, placebo-controlled trial, 2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Glaxo-Smith-Kline.
● A Randomized, double-blind comparison of placebo and atomoxetine hydrochloride given once a day in adults with Attention-Deficit/Hyperactivity Disorder: with a secondary examination of impact of treatment on family functioning, 2006-2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● A Multi-Center, Randomized, Double-blind, Parallel Study of The Efficacy and Safety of Two Weeks of Dosing of Various Formulations and Doses of NG2-73 and Placebo for Sleep Initiation in Primary Insomniacs, 2006-2007. Principal Investigator: R. Bart Sangal, M.D. Supported by Neurogen.
● A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging study of the safety and efficacy of ABT-894 in adults with Attention Deficit-Hyperactivity Disorder (ADHD), 2007. Principal Investigator: R. Bart Sangal, M.D. Supported by Abbott.
● A Six-week, double-blind, randomized, placebo-controlled, parallel group, efficacy and safety, sleep lab trial with Org 50081 in patients with chronic primary insomnia, 2007. Principal Investigator: R. Bart Sangal, M.D. Supported by Organon.
● Fifty-two weeks, open-label extension trial to evaluate safety and efficacy of Org 50081 in outpatients with chronic primary insomnia who completed Clinical Trial Protocol 176001 or 176002, 2007-2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Organon.
● A Phase II1, randomized, double-blind, placebo-controlled, incomplete-block, two-period crossover clinical trial to study the safety and efficacy of MK-0249 for adult patients, ages 18 to 55, with Attention Deficit Hyperactivity Disorder (ADHD), 2007-2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Merck.
● A prospective, open-label, multi-center, dose-optimization study evaluating the efficacy, safety and tolerability of Vyvanse 20-70 mg in children aged 6-12 diagnosed with ADHD, 2007-2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Shire.
● A phase IIIb, randomized, double-blind, multi-center, parallel-group, placebo-controlled, dose optimization study, designed to evaluate the efficacy and safety of methylphenidate transdermal system (MTS) in adolescents aged 13-17 years with attention-deficit/hyperactivity disorder (ADHD), 2007-2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Shire.
● A Multicenter, randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of VEC-162 (20 mg/day and 50 mg/day) in the treatment of primary insomnia, 2007-2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Vanda.
● A Pilot, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 study of the safety, tolerability and efficacy of 0.7 mg/kg/day and 1.4 mg/kg/day ABT-089 in the treatment of children with Attention-Deficit/Hyperactivity Disorder (ADHD), 2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Abbott.
● A Pilot, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 study of the safety, tolerability and efficacy of 40 mg qd and 80 mg qd ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD), 2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Abbott.
● The long-term safety and tolerability of ABT-089 in children with Attention-Deficit/Hyperactivity Disorder (ADHD): an open-label extension study, 2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Abbott.

● The long-term safety and tolerability of ABT-089 in children with Attention-Deficit/Hyperactivity Disorder (ADHD): an open-label extension study for subjects completing study M10-346, 2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Abbott.
● A phase 2, randomized, double-blind, placebo- and active-comparator-controlled study of the safety and efficacy of LY2624803 in outpatients with insomnia, 2008 – 2010. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● A phase III, randomized, double-blind, multi-center, parallel group, placebo-contolled, forced-dose titration, safety and efficacy study of lisdexamfetamine dimesylate (LDX) in adolescents aged 13-17 with attention-deficit/hyperactivity disorder (ADHD), 2008-2009. Principal Investigator: R. Bart Sangal, M.D. Supported by Shire.
● A phase III, open-label, extension, multi-center, safety and efficacy study of lisdexamfetamine dimesylate (LDX) in adolescents aged 13-17 with attention-deficit/hyperactivity disorder (ADHD), 2008 – 2010. Principal Investigator: R. Bart Sangal, M.D. Supported by Shire.
● Single Dose, open label safety, tolerability, pharmacokinetic and pharmacodynamic evaluation of three different eplivanserin doses in children aged 6-17 years with insomnia of various origins, 2009. Principal Investigator: R. Bart Sangal, M.D. Supported by Sanofi-Aventis.
● LY377604 + sibutramine hydrochloride monohydrate: a phase 2 weight loss efficacy study in overweight/obese men and women, 2009-2010. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
● A randomized, placebo-controlled, double-blind, fixed-dose study of the efficacy and safety of eszopiclone in children (6 to 11 years) and adolescents (12 to 17 years) with Attention-Deficit/Hyperactivity Disorder-associated Insomnia, 2009-2011. Principal Investigator: R. Bart Sangal, M.D. Supported by Sunovion.
● A long-term, open-label, safety study of eszopiclone in children (6 to 11 years) and adolescents (12-17 years) with Attention-Deficit/Hyperactivity Disorder-associated Insomnia, 2009-2011. Principal Investigator: R. Bart Sangal, M.D. Supported by Sunovion.
● A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group study to evaluate the safety and efficacy of MK-4305 in Patients with Primary Insomnia – Study B, 2010-2011. Principal Investigator: R. Bart Sangal, M.D. Supported by Merck.
● A Phase 3, Double-blind, Randomized, Multi-center, Placebo-controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once-daily Dosing with Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD), 2012. Principal Investigator: R. Bart Sangal, M.D. Supported by Shire.
● A Phase 4, Randomized, Double-blind, Parallel-group, Active-controlled, Dose-optimization safety and efficacy study of SPD489 (VYVANSER) compared with OROS-MPH (CONCERTAR) with a Placebo reference arm, in adolescents aged 13-17 years with Attention-deficit/Hyperactivity disorder (ADHD), 2012-2014. Principal Investigator: R. Bart Sangal, M.D. Supported by Shire.
● A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose titration, safety and efficacy study of SPD489 (VYVANSER) compared with OROS-MPH (CONCERTAR) with a Placebo reference arm, in adolescents aged 13-17 years with Attention-deficit/Hyperactivity disorder (ADHD), 2012-2014. Principal Investigator: R. Bart Sangal, M.D. Supported by Shire.
● Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Forced-dose Titration, Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years with Attention-deficit/Hyperactivity Disorder (ADHD), 2015-2016. Principal Investigator: R. Bart Sangal, M.D. Supported by Shire.
● A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(*R*)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in Subjects with Narcolepsy, 2015-2016. Principal Investigator: R. Bart Sangal, M.D. Supported by Jazz Pharmaceuticals.
● A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP-110 [(*R*)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in Subjects with Obstructive Sleep Apnea (OSA), 2015-2016. Principal Investigator: R. Bart Sangal, M.D. Supported by Jazz Pharmaceuticals.
● A Long-Term, Open-Label Safety and Maintenance of Efficacy Study of JZP-110 [(*R*)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in Subjects with Narcolepsy or Obstructive Sleep Apnea, 2016-2017. Principal Investigator: R. Bart Sangal, M.D. Supported by Jazz Pharmaceuticals.
● A Multicenter, Randomized, Double-blind, Placebo-controlled, Active comparator, Parallel-group study of the efficacy and safety of Lemborexant in subjects 55 and older with Insomnia Disorder. 2016-2017. Principal Investigator: R. Bart Sangal, M.D.Supported by Eisai.
● A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in Subjects with Parkinson’s Disease and Excessive Sleepiness. 2017-2018. Principal Investigator: R. Bart Sangal, M.D. Supported by Jazz Pharmaceuticals.
● A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults with Idiopathic Hypersomnia. 2018-2019. Principal Investigator: R. Bart Sangal, M.D. Supported by Balance Therapeutics.
● A Multicenter, Fixed-Dose, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of AR19 (Amphetamine Sulfacte) in Adult Subjects (Ages 18-55) with Attention Deficit Hyperactivity Disorder (ADHD). 2018. Principal Investigator: R. Bart Sangal, M.D. Supported by Arbor Pharmaceuticals.
● A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-label Safety Extension. 2020-2021. Principal Investigator: R. Bart Sangal, M.D. Supported by Jazz Pharmaceuticals.
● A Phase 2, Double-blind, Placebo-controlled, Parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and efficany of 2 mg and 4 mg SUVN-G3031 compared to placebo in patients with narcolepsy with and without cataplexy. 2020-2023. Principal Investigator: R. Bart Sangal, M.D. Supported by Suven Life Sciences.
● A Four-week, Double-blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol extended release) in Adults for the Treatment of Narcolepsy. 2021-2022. Principal Investigator: R. Bart Sangal, M.D. Supported by NLS Pharmaceuticals.
● A 6-Month Multicenter, Open-Labelled Extension of the Clinical Trial NLS-1021 in Narcoleptic Patients with and without Cataplexy. 2021-2022. Principal Investigator: R. Bart Sangal, M.D. Supported by NLS Pharmaceuticals.
● Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of Atomoxetine/Aroxybutynin (AD109) to Atomoxetine alone or Placebo in Obstructive Sleep Apnea. 2021-2022. Principal Investigator: R. Bart Sangal, M.D. Supported by Apnimed.
● A Double-Blind, Placebo-controlled, randomized withdrawal study to evaluate the safety and efficacy of Pitolisant in adult patients with Idiopathic Hypersomnia. 2022-2023. Principal Investigator: R. Bart Sangal, M.D. Supported by Harmony Biosciences.
● An Open-Label Study to evaluate the long-term safety and effectiveness of Pitolisant in adult patients with Idiopathic Hypersomnia who completed study HBS-101-CL-010. 2022-. Principal Investigator: R. Bart Sangal, M.D. Supported by Harmony Biosciences.
● A Phase 2, Placebo-controlled, double-blind, randomized withdrawal study to determine the safety and efficacy of oral SDX in patients with Idiopathic Hypersomnia (IH). 2022-2023. Principal Investigator: R. Bart Sangal, M.D. Supported by Kem-Pharm.
● A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy. 2023-2024. Principal Investigator: R. Bart Sangal, M.D. Supported by Jazz.
● Phase 3 randomized double-blind placebo-controlled 1-year parallel-arm study to compare a fixed dose combination of aroxybutynin/atomoxetine (ad109) to placebo in obstructive sleep apnea, 2023-2025. Principal Investigator: R. Bart Sangal, M.D. Supported by Apnimed.
● A Phase II/III, Randomised, Double-Blind Clinical Trial to Determine the Safety and Efficacy of IHL-42X in Subjects with Obstructive Sleep Apnoea Who Are Intolerant, Non-Compliant, or Naïve to Positive Airway Pressure, 2024. Principal Investigator: R. Bart Sangal, M.D. Supported by Incannex Healthcare Ltd.
● A Phase 3 Open Label continuation Protocol of a fixed dose combination of Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea. 2024-2025. Principal Investigator: R. Bart Sangal, M.D. Supported by Apnimed.
● A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of FT218 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-Label Safety Extension. 2024-2025. Principal Investigator: R. Bart Sangal, M.D. Supported by Avadel.
● A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1. 2024. Principal Investigator: R. Bart Sangal, M.D. Supported by Alkermes.
● Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2, 2024-2025. Principal Investigator: R. Bart Sangal, M.D. Supported by Alkermes.
● An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia, 2025. Principal Investigator: R. Bart Sangal, M.D. Supported by Alkermes.
● Phase 2a, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects with Narcolepsy and Idiopathic Hypersomnia – (CRYSTAL-1). 2025. Principal Investigator: R. Bart Sangal, M.D. Supported by Centessa.
● A Phase 1b, Open-Label Study of Pitolisant Delayed-Release in Adult Participants with Narcolepsy. 2025. Principal Investigator: R. Bart Sangal, M.D. Supported by Harmony Biosciences.
● A Phase 2, Long-term Extension Study of the Safety and Efficacy of ORX750 in Participants with Narcolepsy and Idiopathic Hypersomnia Who Completed a Sponsored ORX750 Clinical Trial. 2025. Principal Investigator: R. Bart Sangal, M.D. Supported by Centessa.
● A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX142 in Participants with Narcolepsy and Idiopathic Hypersomnia, 2025. Principal Investigator: R. Bart Sangal, M.D. Supported by Centessa.

PRESENTATIONS

Invited/refereed presentations at international/national meetings:
● Sangal R, Thomas L. Mean Sleep Latency and Mean Maintenance of Wakefulness. Assoc Prof Sleep Societies, San Diego, 1988.
● Sangal, R. Multiple Sleep Latency Test and Retest in Narcolepsy. American Med EEG Soc, Lexington, 1988.
● Sangal R, Thomas L, Mitler MM. Maintenance of Wakefulness Test Versus Multiple Sleep Latency Test: A Factor Analytic Approach. Assoc Prof Sleep Societies, Toronto, 1991.
● Sangal R Thomas L. Narcolepsy: Improvement in MSLT with Pemoline. Assoc Prof Sleep Societies, Toronto, 1991.
● Sangal R, Thomas L. Obstructive Sleep Apnea: Improvement in Somnolence with Continuous Positive Airway Pressure. Assoc Prof Sleep Societies, Toronto, 1991.
● Sangal R, Thomas L. Tests for Measuring Objective Change in Daytime Sleepiness with Treatment. American Electroencephalographic Society, Philadelphia, 1991.
● Sangal RB, Thomas L, Mitler MM. Disorders of Excessive Sleepiness: Treatment Improves Ability to Stay Awake but Does Not Reduce Sleepiness. Assoc Prof Sleep Societies, Phoenix, 1992.
● Sangal RB, Sangal JM. Topography of Auditory and Visual P300 in Normal Adults. American EEG Society, New Orleans, 1993.
● Sangal JM, Sangal RB. Topography of Auditory and Visual P300 in Normal Children. American EEG Society, New Orleans, 1993.
● Sangal RB, Sangal JM. Severe Daytime Sleepiness causes abnormal Auditory P300 Latency Topography with normal Visual P300 Topography. American EEG Society, New Orleans, 1993.
● Sangal RB, Sangal JM. Profound Obstructive Sleep Apnea causes abnormal Visual P300 Latency Topography with normal Auditory P300 Topography. American EEG Society, New Orleans, 1993.
● Sangal RB, Sangal JM. Closed head injuries, excessive daytime sleepiness, and abnormal visual P300 brain topography. Assoc Prof Sleep Societies, Boston, 1994.
● Sangal RB, Sangal JM. P300 brain topography is differentially affected by somnolence of different types. Assoc Prof Sleep Societies, Boston, 1994.
● Sangal RB, Sangal JM. Sleep apnea impairs visual cognitive function as measured by P300 brain topography. Assoc Prof Sleep Societies, Boston, 1994.
● Sangal RB, Sangal JM. Measures of sleepiness (maintenance of wakefulness test and multiple sleep latency test) and P300 amplitudes and latencies measure different abilities in patients with sleep disorders. Assoc Prof Sleep Societies, Boston, 1994.
● Sangal JM, Sangal RB, Persky B. P300 Topography predicts treatment response in attention deficit disorder. American EEG Society, Chicago, 1994.
● Sangal RB, Sangal JM. P300 Latency: Abnormal in Sleep Apnea with Somnolence and Idiopathic Hypersomnia, but Normal in Narcolepsy. American Psychiatry Electrophysiology Association, Miami, 1995.
● Sangal RB, Semery JP, Belisle C. Computerized Analysis of Abnormal Human Sleep offers Reasonable Results. Assoc Prof Sleep Societies, Washington, 1996.
● Sangal RB, Sangal JM, Belisle C. MWT and ESS Measure Different Abilities in 41 Patients with Snoring and Daytime Sleepiness. Assoc Prof Sleep Societies, San Francisco, 1997.
● Sangal RB, Mitler MM, Sangal JM, US Modafinil in Narcolepsy Study Group. MSLT, MWT and ESS: Indices of Sleepiness in 522 Drug-free Patients with Narcolepsy. Assoc Prof Sleep Societies, San Francisco, 1997.
● Mitler MM, Walsleben J, Sangal RB. US Modafinil in Narcolepsy Study Group. MWT Sleep Latencies for 530 Drug-Free Patients with Narcolepsy. Assoc Prof Sleep Societies, San Francisco, 1997.
● Sangal RB, Sangal JM, Belisle C. Patients with Narcolepsy have longer Auditory and Visual P300 Latencies. Assoc Prof Sleep Societies, New Orleans, 1998.
● Sangal RB, Sangal,JM, Belisle C. P300 Measures in Narcolepsy predict Treatment Response to Modafinil. Assoc Prof Sleep Societies, New Orleans, 1998.
● Sangal,RB, Sangal JM, Belisle C. Predicting Treatment Response in Narcolepsy using the P300. International Society for Brain Electromagnetic Topography/ EEG and Clinical Neuroscience Society, New Orleans, 1998.
● Sangal,RB. Cognitive Evoked Potentials (P300 Topography) in the Treatment of Attention Deficit. EEG and Clinical Neuroscience Society, Macon, 2000.
● Sangal RB, Sangal JM, Ollila M. Rating Scales for Inattention and Sleepiness are correlated in Sleep Disordered Patients, but not in Patients with Attention Deficit-Hyperactivity Disorder. Assoc Prof Sleep Societies, Chicago, 2001.
● Sangal RB, Sangal JM, Ollila M. Polysomnograhic Evidence of Normal Sleep Related Respiration in Patients with Attention Deficit-Hyperactivity Disorder. Assoc Prof Sleep Societies, Seattle, 2002.
● Sangal RB, Sangal JM. The Epworth Sleepiness Scale Does Not Measure Perceived Sleepiness in Patients with Sleep Apnea. Assoc Prof Sleep Societies, Chicago, 2003.
● Sangal RB, Sangal JM. Patients with Attention Deficit Hyperactivity Disorder Have Normal Sleep on Polysomnography. Assoc Prof Sleep Societies, Chicago, 2003.
● Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Feng MS, Kelsey D. Effects of Atomoxetine and Methylphenidate on Sleep in Children with ADHD. Assoc Prof Sleep Societies, Philadelphia, 2004.
● Sangal RB, Stone M. Scale of Wake Ability and Fatigue: A New Scale with High Internal Consistency, Convergent and Discriminant Validity, and Test-Retest Reliability. Assoc Prof Sleep Societies, Seattle, 2009.
● Sangal RB. A Reliable and Valid Instrument for Measuring Wake Inability and Fatigue: The Sangal Wake Inability and Fatigue Test. Assoc Prof Sleep Societies, Minneapolis, 2010.
● Sangal RB. How to Evaluate and Diagnose Sleep Apnea. Michigan State Medical Society, Troy, 2014.Sangal RB. Achieving 90% Positive Airway Pressure (CPAP) Adherence. Assoc Prof Sleep Societies, Seattle, 2015.
● Sangal RB. Getting to 90% PAP Adherence. Michigan Academy of Sleep Medicine, Ann Arbor, 2015.
● Sangal RB. Diagnosing Attention Deficit (ADHD, Attention-Deficit/Hyperactivity Disoder) and using an EEG based tool to confirm the diagnosis. Michigan State Medical Society, Troy, 2015.
● Sangal RB. Neurophysiology of Attention Deficit (including an EEG based tool to predict response to medicines and pharmacology of useful medicines). Michigan State Medical Society, Troy, 2015.
● Sangal RB, Mignot E, Ruoff C, Nichols DA, Steininger TL, Fuller DS, et al. Subjective sleep quality with low sodium oxybate treatment in narcolepsy: results from the DUET study. Assoc Prof Sleep Societies, Seattle, 2025.
● Ruoff C, Schneider LD, Sangal RB, Nichols DA, Steininger TL, Fuller DS, et al. Sleep architecture with low sodium oxybate treatment in narcolepsy: results from the DUET study. Assoc Prof Sleep Societies, Seattle, 2025.
● Foldvary-Schaefer N, Sangal RB, Maski K, Nichols DA, Steininger TL, Dai J, et al. Sleep Actigraphy in participants with Narcolepsy or Idiopathic Hypersomnia taking low-sodium oxybate: Results from the DUET study. World Sleep Congress, Singapore, 2025.
● Ruoff CM, Schneider LD, Sangal RB, Nichols DA, Steininger TL, Fuller DS, et al. Sleep Architecture with low-sodium oxybate treatment in Narcolepsy: Results from the DUET study. World Sleep Congress, Singapore, 2025.

Invited Seminars and Grand Rounds

● Sangal RB. Is ADHD a Sleep Disorder? The Spectrum of Developmental Disabilites, Johns Hopkins School of Medicine: Kennedy-Krieger Institute, Baltimore, MD, 2007.
● Grand Rounds to William Beaumont Hospital, Royal Oak, Department of Medicine
● Grand Rounds to William Beaumont Hospital, Royal Oak, Department of Pediatrics
● Grand Rounds to Wayne State University School of Medicine, Department of Psychiatry, 2007.
● Grand Rounds to St Mary’s Hospital, Livonia, Department of Medicine, 2015.

Scroll to Top